Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-06
2006-06-06
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S427000, C424S433000
Reexamination Certificate
active
07056893
ABSTRACT:
Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.
REFERENCES:
patent: 4474768 (1984-10-01), Bright
patent: 4512982 (1985-04-01), Hauske et al.
patent: 4517359 (1985-05-01), Kobrehel et al.
patent: 4551456 (1985-11-01), Katz
patent: 4692454 (1987-09-01), Mich et al.
patent: 4851415 (1989-07-01), Mich et al.
patent: 5124154 (1992-06-01), Babcock et al.
patent: 5188826 (1993-02-01), Chandrasekaran et al.
patent: 5192535 (1993-03-01), Davis et al.
patent: 5225399 (1993-07-01), Zasloff et al.
patent: 5239059 (1993-08-01), Zasloff et al.
patent: 5340572 (1994-08-01), Patel et al.
patent: 5424290 (1995-06-01), Maloy et al.
patent: 5441939 (1995-08-01), Yang
patent: 5498699 (1996-03-01), Djokic et al.
patent: 5520518 (1996-05-01), Taguchi
patent: 5538738 (1996-07-01), Ritter et al.
patent: 5578572 (1996-11-01), Horwitz et al.
patent: 5605889 (1997-02-01), Curatolo et al.
patent: 5610198 (1997-03-01), Barry, III et al.
patent: 5631004 (1997-05-01), Cagle et al.
patent: 5679665 (1997-10-01), Bergamini et al.
patent: 5747058 (1998-05-01), Tipton et al.
patent: 5767153 (1998-06-01), Bowman et al.
patent: 5783561 (1998-07-01), Horwitz et al.
patent: 5804558 (1998-09-01), Lehrer et al.
patent: 5807830 (1998-09-01), Morozov et al.
patent: 5814655 (1998-09-01), Patel et al.
patent: 5872104 (1999-02-01), Vermeulen et al.
patent: 5888973 (1999-03-01), Lambert, Jr.
patent: 5912331 (1999-06-01), Wilkening
patent: 5977171 (1999-11-01), Bowman et al.
patent: 6159458 (2000-12-01), Bowman et al.
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6265444 (2001-07-01), Bowman et al.
patent: 6277829 (2001-08-01), Asero et al.
patent: 6309630 (2001-10-01), Patel et al.
patent: 6378526 (2002-04-01), Bowman et al.
patent: 6397849 (2002-06-01), Bowman et al.
patent: 6569443 (2003-05-01), Dawson et al.
patent: 6861411 (2005-03-01), Ahmed
patent: 2003/0171307 (2003-09-01), Boettner
patent: 0 126 684 (1984-11-01), None
patent: 0 142 426 (1985-05-01), None
patent: 0 298 650 (1989-01-01), None
patent: 0 391 909 (1990-10-01), None
patent: 0 445 743 (1991-09-01), None
patent: 0 445 743 (1991-09-01), None
patent: 0 467 331 (1992-01-01), None
patent: 0 677 530 (1995-10-01), None
patent: 0 679 400 (1995-11-01), None
patent: 0 711 546 (1996-05-01), None
patent: 0 879 823 (1998-11-01), None
patent: 0 925 789 (1999-06-01), None
patent: 0925 789 (1999-06-01), None
patent: 1075837 (2001-02-01), None
patent: 11-240838 (1999-09-01), None
patent: WO 89/00576 (1989-01-01), None
patent: WO 95/09601 (1995-04-01), None
patent: WO 96 19489 (1996-06-01), None
patent: WO 96 20010 (1996-07-01), None
patent: WO 96/39995 (1996-12-01), None
patent: WO PCT98/17280 (1998-04-01), None
Drug Approvals for Jan. 1997, Center for Drug Evaluation and Research, USDA (p. 1, 2; thromax).
Zithromax for IV Infusion Only, Pfizer Labs, New York, NY (2001).
Azithromycin, Official Monographs, USP, vol. 25, pp. 188-190.
Bailey et al., Lancet vol. 3rdpp. 453-456 (1993).
First Meeting of the WHO Alliance for the Global Elimination of Trachoma, Geneva, Jun. 30-Jul. 1, 1997.
Robert E. Leonard, II et al.,Erythromycin, Clarithromycin, and Azithromycin, 1997, Textbook of Ocular Pharmacology, pp. 515-523.
Robert H. Cross, et al.Corneal Pharmacokinetics of Topical Clarithromycin, Apr. 1995, Investigative Ophthalmology & Visual Science, vol 36, No. 5, pp. 965-968.
A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Abstract XP-002161953 Biosis Information Service, Philadelphia, PA, 1997.
Oral vs. topical erythromycin therapies for chlamydial conjunctivitis. Abstract XP-002161954, Biosis Information Services, Philadelphia, PA, 1982.
Corneal pharmacokinetics of topical clarithromycin. Abstract XP-002161955, Biosis Information Service, Philadelphia, PA, 1995.
Jururatanasirikul, S., et al.,Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrobial Agents Chemotherapy, 40:825-826(1996).
Thylefors, B.Azithromycin: A new opportunity for control of trachoma. WHO Drug Information 10(3):132-133 (1996).
Programme for the Prevention of Blindness and Deafness Alliance for the Global Elimination of Trachoma, “Planning for the Global Elimination of Trachoma (GET) Repport of the WHO Consultation”, Geneva, Switzerland (Nov. 25 & 26, 1996).
Programme for the Prevention of Blindness and Deafness Alliance for the Global Elimination of Trachoma, “Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma”, Geneva, Switzerland (Jun. 30-Jul. 1, 1997).
Programme for the Prevention of Blindness and Deafness, “Report of the Second Meeting of the WHO Alliance for the Global Elination of Trachoma”, Geneva, Switzerland (Jan. 12-14, 1998).
Prevention of Blindness and Deafness Geneva, Switzerland, “Report of the Third Meeting of the WHO Alliance for the Global Elimination of Trachoma”, Quarzazate, Morocco (Oct. 19-20, 1998).
Dawson et al, A comparison of Oral Azithromycin with Topical Oxytetracycline/Polymyxin for the Treatment of Trachoma in Children, Clinical Infections Diseases 1997:24 (Mar.) 363-368 (full copy).
Bowman Lyle M.
Roy Samir
Insite Vision, Inc.
Peselev Elli
Sughrue & Mion, PLLC
LandOfFree
Topical treatment for prevention of ocular infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical treatment for prevention of ocular infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical treatment for prevention of ocular infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679508